Theriva Biologics, Inc.
TOVX
$0.31
-$0.01-3.58%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 541.73% | -17.50% | -10.29% | -5.35% | -22.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 179.70% | -15.30% | -25.23% | -23.53% | -12.86% |
| Operating Income | -179.70% | 15.30% | 25.23% | 23.53% | 12.86% |
| Income Before Tax | -57.02% | 16.28% | 24.74% | -101.72% | -52.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.02% | 16.28% | 18.92% | -133.91% | -63.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.02% | 16.28% | 18.92% | -133.91% | -63.57% |
| EBIT | -179.70% | 15.30% | 25.23% | 23.53% | 12.86% |
| EBITDA | -181.40% | 15.16% | 25.19% | 23.68% | 13.05% |
| EPS Basic | 81.96% | 79.36% | 80.17% | -40.57% | -27.92% |
| Normalized Basic EPS | 66.84% | 78.63% | 81.29% | 52.54% | 29.41% |
| EPS Diluted | 81.96% | 79.36% | 80.17% | -40.57% | -27.92% |
| Normalized Diluted EPS | 66.84% | 78.63% | 81.29% | 52.54% | 29.41% |
| Average Basic Shares Outstanding | 770.57% | 305.66% | 308.92% | 66.41% | 27.88% |
| Average Diluted Shares Outstanding | 770.57% | 305.66% | 308.92% | 66.41% | 27.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |